Latest Content

Will Shrank, Aradigm Health’s CEO, discusses the importance of transparency in healthcare payments to build trust and reduce waste.

In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk profile for AstraZeneca's Truqap, FDA approves Axsome Therapeutics' Auvelity, and Pharmaceutical Executive speaks with Jeff Golfman on how global disruptions are cascading through the pharmaceutical supply chain.

FDA advisory panel backs Truqap combination in PTEN-deficient prostate cancer, signaling potential expansion into biomarker-defined mHSPC population with limited treatment options.

Jeff Golfman, founder and president of Send 123, in a conversation with Pharmaceutical Executive, discusses how rising geopolitical tensions around Iran and broader global disruptions are reshaping pharmaceutical and medical supply chains.

FDA approves Auvelity for Alzheimer’s-related agitation, marking the first therapy targeting NMDA and sigma-1 receptors for this high-burden neuropsychiatric symptom and expanding treatment options for millions of patients.

Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.

Synchronizing sales and marketing around a unified, customer-centric approach is essential for pharmaceutical companies seeking growth and competitive advantage.

In the final part of his interview, Jeff Golfman discusses how data-driven supply chain mapping and collaborative procurement models can gain traction as companies move beyond cost-focused sourcing to strengthen resilience.

Innomar’s VP of commercial strategy and innovation discusses the shifting global landscape and building relationships with pharma manufacturers.

In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US prescription drug spending is projected to surpass $1 trillion in 2026, and Inizio launches a next-generation hub services model aimed at simplifying patient access and support.

Inizio launches integrated hub services model to streamline patient access, reimbursement, and adherence, reflecting a broader industry shift toward data-driven, end-to-end patient support strategies.

A report from American Society of Health-System Pharmacists projects U.S. prescription drug spending to surpass $1T in 2026, driven largely by surging demand for GLP-1 weight-loss therapies.

Sanofi is appointing Belén Garijo chief as director and chief executive officer after its annual meeting, underscoring the company's leadership and governance changes.